Karin Vanderkerken
Overview
Explore the profile of Karin Vanderkerken including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
4067
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Egan H, Treacy O, Lynch K, Leonard N, OMalley G, Reidy E, et al.
Cell Rep
. 2023 May;
42(5):112475.
PMID: 37167967
Immunosuppressive tumor microenvironments (TMEs) reduce the effectiveness of immune responses in cancer. Mesenchymal stromal cells (MSCs), precursors to cancer-associated fibroblasts (CAFs), promote tumor progression by enhancing immune cell suppression in...
12.
Van der Vreken A, Oudaert I, Ates G, Faict S, Vlummens P, Satilmis H, et al.
J Pathol
. 2023 Feb;
260(2):112-123.
PMID: 36807305
Multiple myeloma (MM) remains an incurable haematological malignancy despite substantial advances in therapy. Hypoxic bone marrow induces metabolic rewiring in MM cells contributing to survival and drug resistance. Therefore, targeting...
13.
Fan R, Satilmis H, Vandewalle N, Verheye E, Vlummens P, Maes A, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36650020
Background: Immunotherapy emerged as a promising treatment option for multiple myeloma (MM) patients. However, therapeutic efficacy can be hampered by the presence of an immunosuppressive bone marrow microenvironment including myeloid...
14.
Fan R, De Beule N, Maes A, de Bruyne E, Menu E, Vanderkerken K, et al.
Front Immunol
. 2022 Oct;
13:1016059.
PMID: 36304465
The success of immunotherapeutic approaches in hematological cancers is partially hampered by the presence of an immunosuppressive microenvironment. Myeloid-derived suppressor cells (MDSC) are key components of this suppressive environment and...
15.
Satilmis H, Verheye E, Vlummens P, Oudaert I, Vandewalle N, Fan R, et al.
J Pathol
. 2022 Oct;
259(1):69-80.
PMID: 36245401
While multi-drug combinations and continuous treatment have become standard for multiple myeloma, the disease remains incurable. Repurposing drugs that are currently used for other indications could provide a novel approach...
16.
Muylaert C, Van Hemelrijck L, Maes A, de Veirman K, Menu E, Vanderkerken K, et al.
Front Oncol
. 2022 Sep;
12:979569.
PMID: 36059621
Drug resistance (DR) of cancer cells leading to relapse is a huge problem nowadays to achieve long-lasting cures for cancer patients. This also holds true for the incurable hematological malignancy...
17.
Oudaert I, Van der Vreken A, Maes A, de Bruyne E, de Veirman K, Vanderkerken K, et al.
Exp Hematol Oncol
. 2022 Sep;
11(1):49.
PMID: 36050788
Cancer cells are well-known for their capacity to adapt their metabolism to their increasing energy demands which is necessary for tumor progression. This is no different for Multiple Myeloma (MM),...
18.
Vlummens P, Verhulst S, de Veirman K, Maes A, Menu E, Moreaux J, et al.
Front Cell Dev Biol
. 2022 Jun;
10:879057.
PMID: 35757005
Multiple myeloma (MM) is an incurable clonal plasma cell malignancy. Subsets of patients have high-risk features linked with dismal outcome. Therefore, the need for effective therapeutic options remains high. Here,...
19.
De Beck L, Awad R, Basso V, Casares N, De Ridder K, De Vlaeminck Y, et al.
Front Immunol
. 2022 May;
13:799636.
PMID: 35634329
Immunotherapy has improved the treatment of malignant skin cancer of the melanoma type, yet overall clinical response rates remain low. Combination therapies could be key to meet this cogent medical...
20.
Wang F, Oudaert I, Tu C, Maes A, Van der Vreken A, Vlummens P, et al.
Cancer Lett
. 2022 Mar;
535:215649.
PMID: 35315341
Multiple myeloma (MM) cells derive proliferative signals from the bone marrow (BM) microenvironment via exosomal crosstalk. Therapeutic strategies targeting this crosstalk are still lacking. Bortezomib resistance in MM cells is...